分类

BioQuiddity和李氏大药房达成协议 在中国大陆及港澳台地区对两种输液制品进行商业化

2015年8月24日

摘要:专注于大批量即用型不溶性药物开发和商业化的专业制药公司BioQuiddity和在亚洲运营超过20年的生物制药公司(香港)李氏大药房今日宣布签署战略许可证和供应协议,该协议将用于Bioquiddity的罗哌卡因和异丙酚两种输液制品在中国大陆和港澳台地区的注册与商业化。

BioQuiddity Incorporated, a specialty pharmaceutical company focused on the development and commercialization of large volume ready-touse infusible pharmaceuticals, and Lee’s Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”, SEHK Stock Code: 0950), a biopharmaceutical company with over 20 years of operation in Asia, today announced the signing of a strategic license and supply agreement for the registration and commercialization of BioQuiddity’s ropivacaine and propofol infusion pharmaceutical products in the People’s Republic of China, Taiwan, Hong Kong, and Macau. BioQuiddity’s unit-dose infusible pharmaceuticals are comprised of the pharmaceutical, delivery system and administration line in a self-contained, single use, ready-to-use presentation. The ropivacaine pharmaceutical is prefilled with 0.2% ropivacaine and is intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQuiddity’s propofol infusion pharmaceutical features both programmable flow and bolus capabilities. Josh Kriesel, President and CEO of BioQuiddity, stated, “We are excited to collaborate with Lee’s Pharm as we pursue our goal of setting a new standard of care in the presentation and administration of infusible pharmaceuticals throughout the world. Lee’s Pharm’s extensive infrastructure and proven marketing teamwill be the key in bringing BioQuiddity’s proprietary unit-dose, large volume infusion pharmaceuticals to the Asia Pacific region. We are extremely pleased to add another distinguished partner to our worldwide network.” Dr. Li Xiaoyi, Executive Director and Chief Executive Officer of Lee’s Pharm, remarked, “We are honored to partner with BioQuiddity to bring the two unit-dose infusion pharmaceuticals to the Greater China market. BioQuiddity’s infusion pharmaceuticals offer a new and differentiated mode of bringing infusible pharmaceuticals to our customers and to patients.”

文章出处:李氏大药厂官网
刊载时间:2015年8月24日
原文链接:http://www.leespharm.com/file/news/BioQ_Press_Release_E.pdf